Search review questions

Stereoacuity at near · people with intermittent exotropia, aged 5 to 49 years

Stereoacuity at distance Measured using the Preschool Randot test 3 years after surgery · people with intermittent exotropia, aged 5 to 49 years

Motor alignment at distance fixation Measured using PACT at 6 months · people with intermittent exotropia, aged 5 to 49 years

Motor fusion test · people with intermittent exotropia, aged 5 to 49 years

Stereoacuity at near Loss of ≥ 2 octaves near stereoacuity, measured using the Preschool Randot test 3 years after surgery · people with intermittent exotropia, aged 3 to < 11 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 5 to 49 years

Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged 5 to 49 years

Motor alignment at near fixation Measured using the PACT at 6 months · people with intermittent exotropia, aged over 6 years

Stereoacuity at near · people with intermittent exotropia, aged over 6 years

Stereoacuity at distance Loss of ≥ 2 octaves near stereoacuity Measured using the Preschool Randot test 3 years after surgery · people with intermittent exotropia, aged over 6 years

Motor alignment at distance fixation Measured using the PACT at 1 year · people with intermittent exotropia, aged over 6 years

Motor fusion test Measured using the synoptophore and Titmus fly test at 1 year · people with intermittent exotropia, aged over 6 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged over 6 years

Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged over 6 years

Stereoacuity at distance · people with intermittent exotropia, aged 3 to < 11 years

Motor alignment at distance Change in exotropia control at near fixation, measured from baseline to 3 years using the prism and alternate cover test · people with intermittent exotropia, aged 3 to < 11 years

Motor fusion test · people with intermittent exotropia, aged 3 to < 11 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 3 to < 11 years

Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged 3 to < 11 years

Motor alignment at near fixation Measured using PACT at 6 months · people with intermittent exotropia, aged less than 11 years

Stereoacuity at near Measured using the Preschool Randot, Titmus fly, and Titmus circles tests at 40 cm at 6 months · people with intermittent exotropia, aged less than 11 years

Progression of visual field loss (worsening of one or more stages, accordingto the Glaucoma Staging System‐2) (at 12 months) · participants with primary angle‐closure glaucoma

Mean number of medications to control IOP (at 12 months) · participants with primary angle‐closure glaucoma

Gonioscopic findings (Spaeth grading system) (at 12 months or later) · participants with primary angle‐closure glaucoma

Gonioscopic findings (TISA500) (at 12 months) · participants with primary angle‐closure glaucoma

Gonioscopic findings (TISA750) (at 12 months) · participants with primary angle‐closure glaucoma

Visual acuity (log MAR units) (postoperatively) · participants with primary angle‐closure glaucoma

Adverse effects (at 12 months) · participants with primary angle‐closure glaucoma

Quality of life measures · participants with primary angle‐closure glaucoma

Progression of visual field loss · participants with primary angle closure glaucoma

Mean IOP change from baseline (mmHg) (at 12 months) · participants with primary angle closure glaucoma

Mean number of medications to control IOP (at 12 months) · participants with primary angle closure glaucoma

Mean IOP change from baseline to 12 months (mmHg) · participants with primary angle‐closure glaucoma

Gonioscopic findings (Anterior segment optical coherence tomography parameters) (at 6 months) · participants with primary angle closure glaucoma

Visual acuity (log MAR units) · participants with primary angle closure glaucoma

Adverse effects (at 6 months) · participants with primary angle closure glaucoma

Quality of life measures · participants with primary angle closure glaucoma

Progression of visual field loss (at 12 months) · participants with primary angle‐closure glaucoma

Mean IOP change from baseline to 12 months (mmHg) · participants with primary angle‐closure glaucoma

Mean number of medications to control IOP (at 12 months) · participants with primary angle‐closure glaucoma

Gonioscopic findings · participants with primary angle‐closure glaucoma

Mean best corrected visual acuity (on Snellen chart) (at final · participants with primary angle‐closure glaucoma

Adverse effects (up to 12 months) · participants with primary angle‐closure glaucoma

Mean number of medications to control IOP (at 12 months) · participants with primary angle‐closure glaucoma

Quality of life measures (at 12 months) · participants with primary angle‐closure glaucoma

Gonioscopic findings (Degree of angle closure) (at 12 months or later) · participants with primary angle‐closure glaucoma

Visual acuity (ETDRS letter chart) (at 12 months) · participants with primary angle‐closure glaucoma

Adverse effects · participants with primary angle‐closure glaucoma

Quality of life measures(measured on the EQ‐5D; higher = better) (at 12 months) · participants with primary angle‐closure glaucoma

Progression of visual field loss · participants with primary angle‐closure glaucoma